Tower Research Capital LLC TRC Has $2.05 Million Holdings in Cencora, Inc. (NYSE:COR)

Tower Research Capital LLC TRC boosted its position in Cencora, Inc. (NYSE:COR - Free Report) by 124.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,115 shares of the company's stock after purchasing an additional 5,047 shares during the period. Tower Research Capital LLC TRC's holdings in Cencora were worth $2,048,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Transce3nd LLC bought a new position in shares of Cencora during the 4th quarter worth approximately $122,000. Trajan Wealth LLC boosted its position in Cencora by 5.5% during the fourth quarter. Trajan Wealth LLC now owns 112,446 shares of the company's stock worth $25,264,000 after purchasing an additional 5,885 shares during the period. MML Investors Services LLC increased its holdings in shares of Cencora by 2.8% in the fourth quarter. MML Investors Services LLC now owns 87,852 shares of the company's stock valued at $19,739,000 after purchasing an additional 2,402 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Cencora by 1.5% in the 4th quarter. MetLife Investment Management LLC now owns 53,573 shares of the company's stock valued at $12,037,000 after acquiring an additional 798 shares during the period. Finally, Norinchukin Bank The lifted its position in Cencora by 10.1% during the fourth quarter. Norinchukin Bank The now owns 7,970 shares of the company's stock worth $1,791,000 after acquiring an additional 733 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Price Performance

COR traded up $0.77 during trading on Monday, hitting $286.67. 255,721 shares of the stock traded hands, compared to its average volume of 1,705,792. The business has a 50 day moving average price of $268.09 and a 200 day moving average price of $249.54. The company has a market cap of $55.59 billion, a price-to-earnings ratio of 40.78, a PEG ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio is 31.29%.

Analyst Ratings Changes

Several research firms have recently commented on COR. Wells Fargo & Company upped their target price on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $284.55.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction on Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the transaction, the executive vice president now owns 14,665 shares in the company, valued at approximately $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock worth $13,580,967 over the last quarter. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.